<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20191218045798N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-06-07</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>Effects of Iranian propolis supplementation on chronic kidney disease</public_title>
      <acronym></acronym>
      <scientific_title>Effects of Iranian propolis supplementation on proteinuria, 24 hour urine, serum creatinine, prooxidant-antioxidant Balance, Glycemic indices, quality of life and blood pressure in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-07-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>44</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/48603</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: This study is a randomized, double-blinded, placebo-controlled clinical trial. Among patients with chronic kidney disease (CKD) referred to specialized clinics of Tabriz, 44 patients who met the inclusion criteria were selected by simple sampling. These patients were randomly allocated to intervention or control groups (each with 22 patients), and matching between groups was done based on age and whether or not they had diabetes, Blinding description: Randomization is performed by a person who has no involvement in the process of caring for or following up on patients. After random allocation, by using double-blind method patients are unaware of the type of intervention performed for each group. For blindness, at the beginning of the study, a set of cans containing propolis or placebo capsules are encoded by someone other than the researcher as A or B. Patients are followed up for three months, after which the blindness is broken.</study_design>
      <phase>3</phase>
      <hc_freetext>chronic kidney disease (CKD).</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Subjects in the intervention group received daily 250 mg Propolis extract containing 72 mg total amount of phenolic compounds (2 capsules containing 125 mg Propolis extract, 1 capsule before breakfast and 1 capsule before dinner) for 90 days. Propolis capsules are produced by Asal Shahdineh Golha Company in Isfahan and propolis extract is alcoholic. Intervention 2: Control group: whom in the control group received 1000 mg of placebo daily (Because the final weight of each propolis capsule is 500 mg) for 90 days. Placebo capsules are produced by Asal Shahdineh Golha Company in Isfahan.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Paniz Anvari fard</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.44, 6 meter bahar., mokhaberat street., 35 meter sina.,elgoli., Tabriz town</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5167717998</zip>
        <telephone>+98 41 3381 3665</telephone>
        <email>panizanvari@yahoo.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Paniz Anvari fard</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.44, 6 meter bahar., mokhaberat street., 35 meter sina.,elgoli., Tabriz town</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5167717998</zip>
        <telephone>+98 41 3381 3665</telephone>
        <email>panizanvari@yahoo.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The tendency to participate in the study
Having stage 2 or 3 CKD according to eGFR of 30-89 ml/min per 1.73 m2
Aged 20-80 years old</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>BMI less than 18.5 or more than 35 kg/ m2
Kidney transplant recipients
Pregnancy or breastfeeding
Having any kind of allergy or asthma
Receiving steroids or other immune system suppressors
Taking herbals in the last 3 months
Smoking, Being addicted, consuming alcohol or opioids
Professional athletes
Having chronic inflammatory disease (rheumatoid arthritis, IBD), severe depression, schizophrenia, severe liver failure, liver cirrhosis, cancers, severe infection</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Subjects in the intervention group received daily 250 mg Propolis extract containing 72 mg total amount of phenolic compounds (2 capsules containing 125 mg Propolis extract, 1 capsule before breakfast and 1 capsule before dinner) for 90 days. Propolis capsules are produced by Asal Shahdineh Golha Company in Isfahan and propolis extract is alcoholic.</i_keyword>
      <i_keyword>Control group: whom in the control group received 1000 mg of placebo daily (Because the final weight of each propolis capsule is 500 mg) for 90 days. Placebo capsules are produced by Asal Shahdineh Golha Company in Isfahan</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Improvement in kidney function ( proteinuria, 24 hour urine, serum creatinine ). Timepoint: at the beginning and end of the study. Method of measurement: 24-hour urine collection to measure 24-hour urine volume and proteinuria, Jaffe's method for measuring serum creatinine.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Prooxidant-antioxidant Balance. Timepoint: at the beginning and end of the study. Method of measurement: prooxidant-antioxidant Balance method.</sec_outcome>
      <sec_outcome>Glycemic indices ( FBS, HbA1c, insulin ) and HOMA-IR index. Timepoint: at the beginning and end of the study. Method of measurement: biochemical assessment.</sec_outcome>
      <sec_outcome>Quality of life. Timepoint: at the beginning and end of the study. Method of measurement: questionnaire.</sec_outcome>
      <sec_outcome>Blood pressure. Timepoint: at the beginning and end of the study. Method of measurement: Mercury sphygmomanometer.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-05-18</approval_date>
        <contact_name>ethics committee of tabriz university of medical sciences</contact_name>
        <contact_address>No.44, 6 meter bahar., mokhaberat street., 35 meter sina.,elgoli., Tabriz town Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
